Gilead Aims to Get Its Potential COVID-19 Drug to as Many Patients as Possible

On Friday, Gilead Sciences (NASDAQ: GILD) promised to make its experimental coronavirus treatment, remdesivir, accessible to as many people as possible. Recently released clinical trial results suggest the antiviral can significantly reduce the time of recovery for hospitalized COVID-19 patients.

The Food and Drug Administration is expected to issue an emergency-use authorization for remdesivir in record time. A EUA is not the same as a formal approval for the drug as a treatment, but it will make it easier for providers to administer the antiviral to more patients. 

Hand holding a vial of COVID-19 blood.

Image source: Getty Images.

In a government-sponsored study, a majority of patients treated with remdesivir recovered after 11 days compared to 15 days among those given a placebo. Based on that, the wider use of remdesivir could help hospitals stretch their limited intensive-care resources significantly further.

Treading carefully

While a EUA to treat hospitalized COVID-19 patients seems likely for remdesivir, the FDA will probably wait for results from ongoing clinical trials sponsored by Gilead Sciences before considering full approval. Gilead Sciences is running a study meant to enroll around 1,600 patients with moderate cases of COVID-19  and measure their progress after 11 days of treatment with either remdesivir or standard care.

Gilead's also enrolling an expected 6,000 patients with severe cases of COVID-19 into a study comparing remdesivir to standard care. This one will take a bit longer because investigators aren't taking measurements until day 14, but results that confirm data from the NIH trial would be worth the wait.

In the meantime, Gilead is cranking up production of remdesivir and intends to donate the first 1.5 million doses that roll off the line.

10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of April 16, 2020


Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More